1. Celcuity Projects $2.5B Peak Revenue for Gedatolisib as Pivotal Trials and Launch Plans Advance
Celcuity has laid out a bold commercial forecast, projecting its lead drug candidate, gedatolisib, could achieve up to $2.5 billion in annual peak revenue. This significant financial target is tied directly to the successful execution of the company's ongoing pivotal clinical trials and its parallel preparations for a ...